Trial · NCT06751784
Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
NCT06751784, Phase 2, Recruiting, University of Basel
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression. Trials, record NCT06751784. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06751784
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
- NCT number
- NCT06751784
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 38 participants, estimated
- Lead sponsor
- University of Basel
- Conditions
- Working Memory, Mild to Moderate Depression
- Interventions
- Fampridine SR, Placebo
- First posted
- 2024-12-30
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | High-load working memory performance. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | Letter n-back task which includes a 3-back task assessing working memory. The 3-back task requires participants to respond to a letter repeat with two intervening letters (for example, S-m-b-s-g…). Performance will be quantified with the d' measure controlling for false positives. Parallel versions (different sequences) are used for the four test days. |
| Secondary | Reaction time (for correct 3-back responses). | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | letter n-back task |
| Secondary | Performance in a 0-back task (d') as a measure of attention. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | Letter n-back task.Parallel versions (different sequences) are used for the four test days. |
| Secondary | Adaptive verbal working memory capacity test (SPAN) backward. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | The SPAN is a computer-based, adaptively administered test based on item response theory (Rasch model; Rasch, 1980). In the study, test form S2 (backward digit span) is used, which captures both storage capacity and executive functions (Baddeley, 2010). Adaptive administration allows for precise, efficient, and individually tailored assessment while minimizing floor and ceiling effects. Test scoring is based on the estimation of a continuous person parameter (θ) using weighted maximum likelihood (Warm, 1989). This parameter reflects the individual's latent working memory ability and is additionally converted into a digit span score with decimal precision, allowing for nuanced interpretation (Gignac \& Weiss, 2015). |
| Secondary | Verbal episodic memory performance measured by immediate and delayed word-list recall task. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | In this test a list of 15 selected words will be presented to the participants with a rate of one word per two seconds and the participant should recall the words immediately in writing (immediate recall). Around 15 minutes later the participants are asked to recall the words again (short delay). Number of correct words recalled in each stage is considered as the participant's immediate and delayed recall score respectively. The four 15-words wordlists (A-D) out of the following test are used: Verbaler Lern-und Merkfähigkeitstest, VLMT |
| Secondary | Lexical ability measured using a phonemic verbal fluency task (S-words). | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | Adapted from a subtest of the Regensburger Wortflüssigkeits-Test (RWT). In this task participants should name orally as many words as possible initiating with a special letter in one minute (e.g. Mary, Milk, Mouse, etc. for the letter M) the number of unique meaningful words will be considered as the participant's score.Different letters (B, K, P, M) are used for each test day. |
| Secondary | Planning and Problem solving, key aspects of executive functioningwill be measured with the "Tower of London" (ToL) test. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | In this test, participants will be tasked to rearrange colour balls to match a target arrangement in as few moves as possible. The raw score for planning ability (number of correctly solved trials with the minimum number of ball placements) is consider as the participants score. Parallel version will be used for the four test days. |
| Secondary | Cognitive Flexibility will be assessed through the "Intra-Extra Dimensional Set Shifting (IED)" task. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | Participants are asked to use the given feedback to work out a rule that determines which stimulus (shapes and lines in different combinations) is correct. After six correct responses, the stimuli and/or rule changes. The shifts in rule are initially intra-dimensional and then later extra-dimensional. The highest reached level is considered as the participant's score. Parallel version will be used for the four test days. |
| Secondary | The severity of depressive symptoms will be assessed using MADRS-s (self-rating). | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | The MADRS-s consists of 9 items assessing subjects' mood, inner tension, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 and 6. The total score is calculated by summing the answers of the 9 items, ranging between 0 and 54 (higher scores indicate increased severity). |
| Secondary | The affective working memory will be assessed using an emotioanl 2-back. | Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods | The task follows a classic N-back paradigm with two conditions: 0-back and 2-back. Emotional faces (happy, sad, neutral; male/female) from the Karolinska Directed Emotional Faces set (Lundqvist et al., 1998) are presented for 1500 ms with a 1350 ms inter-stimulus interval. Participants indicate whether each stimulus is a "hit" or "non-hit," based on the current stimulus (0-back) or compared to the stimulus two trials prior (2-back). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Intra/Extra Dimensional Set Shift | Secondary outcome | ConductCognition |
| Tower Planning | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06751784
GET https://conductscience.org/api/trials/v1/NCT06751784/registered